drugset / Trial / NCT00530114
Study to Assess Fixed Dosing of AMG 223 in Subjects With Chronic Kidney Disease on Hemodialysis With Hyperphosphatemia
RandomizedParallel-groupTriple-blindTreatment
Summary
The primary objectives of this study are the following: 1. To demonstrate that AMG 223 will produce a statistically significant reduction in serum phosphorus compared with placebo over a 3 week treatment period in subjects with CKD receiving dialysis 2. To describe a dose response for AMG 223 3. To evaluate the safety and tolerability of AMG 223
Timeline
- Start
- 2008-03
- Primary completion
- 2008-11
- Completion
- 2009-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bixalomer | Small molecule | 1 g | Oral |
| Subject | Bixalomer | Small molecule | 3 g | Oral |
| Subject | Bixalomer | Small molecule | 4 g | Oral |
| Subject | Bixalomer | Small molecule | 5 g | Oral |